STOCK TITAN

Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Rhea-AI Summary

Marker Therapeutics (Nasdaq: MRKR) announced that the FDA has lifted the partial clinical hold on its Phase 2 trial for MT-401, a T cell therapy aimed at treating post-transplant acute myeloid leukemia (AML). This decision allows for the continued enrollment of patients in the trial, which evaluates MT-401's safety and efficacy compared to standard care. The trial, which includes approximately 120 patients in the adjuvant setting and 40 with active disease, aims to assess various survival metrics and remission rates. MT-401 has previously received Orphan Drug designation from the FDA.

Positive
  • FDA lifted the partial clinical hold on the Phase 2 trial for MT-401, enabling patient enrollment to continue.
  • MT-401 targets post-transplant AML, potentially offering a safer treatment option over standard care.
  • Orphan Drug designation granted to MT-401 highlights its potential significance in treating AML.
Negative
  • None.

HOUSTON, Jan. 5, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on the Company's Phase 2 trial investigating the safety and efficacy of MT-401, Marker's lead multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia (AML).  

"We are pleased to move forward with our Phase 2 AML trial of MT-401, which we believe may provide a safe and effective treatment option for patients with post-transplant AML over the standard of care," said Mythili Koneru, M.D., Ph.D., Chief Medical Officer of Marker Therapeutics. "During the partial clinical hold, we continued to open clinical centers to enroll patients in the first half of the safety lead-in of our Phase 2 trial. With the FDA's decision, we will now be able to seamlessly enroll patients in the second half of the safety lead-in, as well as the remainder of the trial. We look forward to working with our clinical sites to continue enrolling patients."

The multicenter Phase 2 AML study is evaluating clinical efficacy of MT-401 in patients with AML in both the adjuvant and active disease setting, following an allogeneic stem-cell transplant. In the adjuvant setting, approximately 120 patients will be randomized 1:1 to either MT-401 at 90 days post-transplant versus standard-of-care observation, while about 40 patients with active disease will receive MT-401 as part of the single-arm group. The trial also includes a safety lead-in expected to enroll six patients.

The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients. Additional objectives include, for the adjuvant group, overall survival and graft-versus-host disease relapse-free survival while additional objectives for the active disease group include overall response rate, duration of response, progression-free survival and overall survival.  

In April 2020, the FDA granted Orphan Drug designation to MT-401 for the treatment of patients with AML following allogeneic stem cell transplant.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts

Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the impact of the COVID-19 pandemic; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401, as well as clinical trials conducted by our collaborators; our manufacturing processes and our ability to use our in-house manufacturing facility to support clinical and commercial demand. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-announces-fda-lifted-partial-clinical-hold-on-phase-2-aml-clinical-trial-301200600.html

SOURCE Marker Therapeutics, Inc.

FAQ

What is Marker Therapeutics' Phase 2 trial focused on?

The Phase 2 trial is focused on evaluating the safety and efficacy of MT-401 in treating post-transplant acute myeloid leukemia (AML).

What did the FDA's decision mean for Marker Therapeutics?

The FDA's decision to lift the partial clinical hold allows Marker Therapeutics to resume patient enrollment in the Phase 2 trial of MT-401.

How many patients are involved in the MT-401 clinical trial?

The trial will involve approximately 120 patients in the adjuvant setting and about 40 patients with active disease.

What objectives are being evaluated in the MT-401 trial?

The trial aims to evaluate relapse-free survival, complete remission rates, overall survival, and other key metrics in patients with AML.

Marker Therapeutics, Inc.

NASDAQ:MRKR

MRKR Rankings

MRKR Latest News

MRKR Stock Data

29.09M
7.84M
12.2%
22.44%
0.78%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HOUSTON